Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) went down by -0.18% from its latest closing price compared to the recent 1-year high of $306.08. The company’s stock price has collected 1.21% of gains in the last five trading sessions. Barron’s reported 16 hours ago that Crispr Therapeutics Is Upgraded After $900 Million Deal
Is It Worth Investing in Vertex Pharmaceuticals Incorporated (NASDAQ :VRTX) Right Now?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) scored a price-to-earnings ratio above its average ratio, recording 21.33 x from its present earnings ratio. Plus, the 36-month beta value for VRTX is at 0.68. Opinions of the stock are interesting as 20 analysts out of 27 who provided ratings for Vertex Pharmaceuticals Incorporated declared the stock was a “buy,” while 3 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $285.04, which is $65.66 above the current price. VRTX currently public float of 258.30M and currently shorts hold a 1.64% ratio of that float. Today, the average trading volume of VRTX was 2.06M shares.
VRTX’s Market Performance
VRTX stocks went up by 1.21% for the week, with a monthly jump of 0.43% and a quarterly performance of -7.16%, while its annual performance rate touched -16.38%. The volatility ratio for the week stands at 1.82% while the volatility levels for the past 30 days are set at 2.08% for Vertex Pharmaceuticals Incorporated. The simple moving average for the period of the last 20 days is 2.14% for VRTX stocks with a simple moving average of -8.37% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Robert W. Baird repeating the rating for VRTX by listing it as a “Outperform.” The predicted price for VRTX in the upcoming period, according to Robert W. Baird is $252 based on the research report published on February 23rd of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $275, previously predicting the price at $315. The rating they have provided for VRTX stocks is “Buy” according to the report published on February 02nd, 2021.
Daiwa Securities gave a rating of “Outperform” to VRTX, setting the target price at $250 in the report published on December 30th of the previous year.
VRTX Trading at 2.59% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.20% of loss for the given period.
Volatility was left at 2.08%, however, over the last 30 days, the volatility rate increased by 1.82%, as shares surge +2.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.51% upper at present.
During the last 5 trading sessions, VRTX rose by +1.21%, which changed the moving average for the period of 200-days by -24.56% in comparison to the 20-day moving average, which settled at $215.47. In addition, Vertex Pharmaceuticals Incorporated saw -7.02% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at VRTX starting from Sanna Bastiano, who sale 1,686 shares at the price of $214.14 back on Apr 05. After this action, Sanna Bastiano now owns 35,834 shares of Vertex Pharmaceuticals Incorporated, valued at $361,046 using the latest closing price.
Liu Joy, the SVP, General Counsel of Vertex Pharmaceuticals Incorporated, sale 5,141 shares at $209.69 during a trade that took place back on Mar 05, which means that Liu Joy is holding 8,253 shares at $1,078,018 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- +46.27 for the present operating margin
- +88.14 for the gross margin
The net margin for Vertex Pharmaceuticals Incorporated stands at +43.67. The total capital return value is set at 35.06, while invested capital returns managed to touch 33.30. Equity return is now at value 35.20, with 25.70 for asset returns.
Based on Vertex Pharmaceuticals Incorporated (VRTX), the company’s capital structure generated 10.85 points at debt to equity in total, while total debt to capital is 9.79. Total debt to assets is 8.02, with long-term debt to equity ratio resting at 10.24. Finally, the long-term debt to capital ratio is 9.24.
When we switch over and look at the enterprise to sales, we see a ratio of 9.10, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 8.18 and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.33.